Portal Hypertension Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceSupport muscle mass; may help with hepatic encephalopathy; liver patients often deficient
Deficiency common in cirrhosis; supports ammonia metabolism and immune function
Supporting Stack
Additional supplements for enhanced resultsMay reduce bacterial translocation and hepatic encephalopathy risk
Supporting Studies (1)
Deficiency very common in liver disease; supports bone and immune health
Supporting Studies (1)
May help with inflammation and liver function; caution with bleeding risk
Supporting Studies (1)
May improve hepatic encephalopathy and fatigue in cirrhosis
Supporting Studies (1)
Antioxidant that may help with liver inflammation; studied in NAFLD
Supporting Studies (1)
Liver disease impairs vitamin K metabolism; needed for clotting factors
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Portal hypertension is increased pressure in the portal vein system, which carries blood from the intestines to the liver. It's most commonly caused by cirrhosis (scarred liver), where blood can't flow easily through the liver. This backup pressure causes serious complications: varices (enlarged veins in the esophagus/stomach that can bleed), ascites (fluid in the abdomen), splenomegaly (enlarged spleen), and hepatic encephalopathy (brain fog from toxins the liver can't clear).
CRITICAL: Portal hypertension is a serious condition requiring comprehensive medical management. Treatment focuses on the underlying liver disease, preventing variceal bleeding (beta-blockers, endoscopic banding), managing ascites (diuretics, salt restriction, paracentesis), and treating/preventing hepatic encephalopathy (lactulose, rifaximin). Advanced cases may need TIPS procedure or liver transplant evaluation. These supplements support nutritional status and may help with complications, but they DO NOT replace medical treatment. Always coordinate with your hepatologist/GI specialist.
* Branched-Chain Amino Acids (BCAAs) are often deficient in cirrhosis patients. Supplementation supports muscle mass and may help prevent/treat hepatic encephalopathy by altering ammonia metabolism.
* Zinc deficiency is very common in cirrhosis. Zinc is needed for ammonia detoxification, and supplementation may help with hepatic encephalopathy.
* Probiotics help maintain gut barrier function, reducing bacterial translocation and ammonia-producing bacteria - both important in preventing encephalopathy.
* Vitamin D deficiency is extremely common in liver disease. Supplementation supports bone health (osteoporosis is common) and immune function.
* Omega-3 Fatty Acids may help with inflammation but use cautiously due to potential bleeding concerns.
* L-Carnitine may help with encephalopathy and fatigue.
* Vitamin E has antioxidant properties that may help with liver inflammation.
* Vitamin K may be needed as the liver produces clotting factors.
Expected timeline: Nutritional support is ongoing. Complications require active medical management. Transplant may be the ultimate treatment for advanced disease.
Clinical Perspective
Portal hypertension: portal pressure gradient (HVPG) >5mmHg; clinically significant >10mmHg (varices risk). Causes: cirrhosis (most common), portal vein thrombosis, schistosomiasis, Budd-Chiari, hepatic vein obstruction. Complications: esophageal/gastric varices (risk: bleeding, mortality 20%), ascites, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome, hepatic encephalopathy, hypersplenism.
CRITICAL: Management hierarchy: 1) Treat underlying cause (stop alcohol, antiviral for hepatitis). 2) Primary prevention of variceal bleed: NSBB (propranolol, nadolol, carvedilol) +/- EVL. 3) Ascites: sodium restriction (<2g/day), diuretics (spironolactone + furosemide), paracentesis. 4) SBP prophylaxis: norfloxacin if indicated. 5) HE: lactulose (titrate to 2-3 soft BMs/day), rifaximin for recurrent. 6) TIPS for refractory ascites/recurrent variceal bleeding. 7) Transplant evaluation for decompensated cirrhosis. Supplements are supportive ONLY.
* BCAAs (B-grade): Muscle support; HE benefit. Meta-analysis: cirrhosis outcomes (PMID: 28131459). Systematic review: HE benefit (PMID: 24176113). 5-15g daily.
* Zinc (B-grade): Ammonia metabolism; common deficiency. Meta-analysis: cirrhosis benefit (PMID: 28107559). Clinical trial: HE improvement (PMID: 22050844). 25-50mg daily.
* Probiotics (B-grade): Gut barrier; ammonia reduction. Meta-analysis: HE prevention (PMID: 28940837). 20-50 billion CFU daily.
* Vitamin D (B-grade): Very common deficiency in CLD. Review: chronic liver disease (PMID: 29161770). 2000-4000 IU daily. Monitor levels.
* Omega-3 Fatty Acids (C-grade): Anti-inflammatory. Systematic review: liver disease (PMID: 27788362). 1-2g daily. Caution: bleeding risk.
* L-Carnitine (C-grade): Energy metabolism. Meta-analysis: HE benefit (PMID: 26070688). 1-2g daily.
* Vitamin E (C-grade): Antioxidant. Review: liver disease (PMID: 22488764). 400-800 IU. Monitor for interactions.
* Vitamin K (C-grade): Coagulation support. Review: chronic liver disease (PMID: 18853929). If deficient/bleeding.
Biomarker targets: HVPG (if measured), Child-Pugh score, MELD score, ammonia (HE), platelet count, INR, albumin, bilirubin, creatinine.
Protocol notes: Nutrition critical: adequate protein (1-1.5g/kg; don't restrict protein for HE - causes sarcopenia), small frequent meals. Salt restriction: <2g/day for ascites. Alcohol cessation: essential in ALD. Varices screening: all cirrhotics need EGD. Beta-blocker target: HR 55-60 or 25% reduction. Acute variceal bleed: emergency - octreotide, antibiotics, EGD, consider TIPS. Ascites: daily weight, avoid NSAIDs (renal), judicious diuretics. HE: lactulose is mainstay; treat precipitants (infection, GI bleed, electrolyte disturbance, constipation). Supplements: avoid high-dose vitamin A (hepatotoxic), iron (unless deficient), excess protein powders. Muscle wasting (sarcopenia): common, associated with poor outcomes - BCAAs, exercise when possible. Transplant: refer if MELD >15, refractory ascites, HE, variceal bleed, hepatocellular carcinoma.